CRISPR

The Readout Damian Garde

STAT Plus: Your morning biotech news roundup

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India

The Readout Damian Garde

STAT Plus: Gene editing has had a big week in the spotlight. Here’s what’s going on

The Readout Damian Garde

STAT Plus: Sarepta’s disappointing data put the FDA in a difficult spot

Biotech Megan Molteni and Adam Feuerstein

STAT Plus: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease

Biotech Adam Feuerstein and Megan Molteni

STAT Plus: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show

Biotech Jason Mast

STAT Plus: In major test for prime editing, scientists successfully correct mutations in monkeys

The Readout Meghana Keshavan

STAT Plus: Johnson & Johnson antiviral pill for dengue shows early efficacy

Biotech Adam Feuerstein

STAT Plus: FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol

The Readout Meghana Keshavan

STAT Plus: Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Live from the 2023 STAT Summit

The Readout Damian Garde

STAT Plus: What if there’s no market for a CRISPR cure?

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs

Biotech Megan Molteni

STAT Plus: In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years

In the Lab Andrew Joseph

To protect chickens from bird flu, researchers try to CRISPR in immunity

Exclusive Jason Mast

STAT Plus: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells

In the Lab Jason Mast

STAT Plus: Carl June unveils a plan for a ‘universal CAR-T’

Biotech Megan Molteni

STAT Plus: Intellia plays down concerns about accidental germline transmission in CRISPR trial

In the Lab Angus Chen

STAT Plus: A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer

Biotech Jason Mast

STAT Plus: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

In the Lab Andrew Joseph

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer’s

Biotech Andrew Joseph

STAT Plus: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy

Biotech Andrew Joseph

STAT Plus: Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia

Biotech Megan Molteni

STAT Plus: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

Biotech Jason Mast

STAT Plus: Gene therapy death not caused by CRISPR, investigators confirm

Biotech Jason Mast

STAT Plus: Doudna talks cost, access issues looming over first CRISPR therapy

Exclusive Jason Mast

STAT Plus: Early findings in gene therapy death suggest CRISPR was not the cause

In the Lab Jason Mast

STAT Plus: Researchers devise new strategies to overcome a key CRISPR flaw

In the Lab Megan Molteni

Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed